Adrenal Suppression and Adrenal Recovery Induced by Megestrol Acetate
Information source: University of Arkansas
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Adrenal Insufficiency
Intervention: megestrol acetate (Drug)
Phase: N/A
Status: Completed
Sponsored by: University of Arkansas Official(s) and/or principal investigator(s): donald l bodenner, Principal Investigator, Affiliation: associate professor
Summary
Megestrol Acetate (MA) is a progesterone-like hormone that has been utilized as a birth
control agent, chemotherapeutic drug, and more recently, to induce appetite and weight gain
in patients malnourished as a result of radiation therapy, chemotherapy, cystic fibrosis,
AIDS, or dementia. The mechanism of MA-stimulated appetite and weight gain is unknown.
Although only approved to combat weight loss associated with AIDS and cancer, MA is
frequently prescribed for long periods of time to prevent or reverse weight loss in nursing
home residents and in elderly patients with serious illnesses in the community. Little data
is available to support this practice. Among its many properties, MA acts as a partial
glucocorticoid agonist, and long term and short term use of MA may results in adrenal
suppression. The rapidity of the onset of MA-induced adrenal suppression and the time
course of resumption of normal adrenal function after discontinuation of MA is completely
unknown. As a consequence, it is unclear whether MA can be given safely for short periods
of time or whether glucocorticoid administration is necessary after abruptly stopping MA
treatment. The increased use of MA in the frail elderly, where even partial adrenal
insufficiency may pose a substantial risk of adrenal crisis after an illness, requires a
clear understanding of these issues. To address these concerns, we will evaluate adrenal
function before, during, and after MA administration in healthy volunteers between the ages
of 60 and 85 years.
Clinical Details
Official title: Evaluation of the Time Course of Adrenal Suppression and Adrenal Recovery After Ingestion of Megestrol Acetate
Study design: Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Health Services Research
Primary outcome: Number of Participants With Adrenal InsufficiencyTime Required for Recovery From Adrenal Suppression to Normal Adrenal Function
Eligibility
Minimum age: 65 Years.
Maximum age: 80 Years.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Elderly males and females
- Age 65-80 years
- With stable (no history of urgent/ emergent care visits with health care provider/s
in the preceding 2 months), medical conditions
Exclusion Criteria:
Subjects will be excluded if they have a history of (H/O):
- Dementia
- Adrenal disease
- Thromboembolism
- Diabetes mellitus
- Liver disease
- Electrolyte abnormalities; or
- Vaginal bleeding
- Hypertriglyceridemia
- CAD with CHF
- Unstable depression
- Schizophrenia; and
- Morbidly obese subjects.
Locations and Contacts
University of Arkansas For Medical Sciences, Little Rock, Arkansas 72205, United States
Additional Information
Starting date: April 2004
Last updated: July 27, 2011
|